Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Acro Biomedical (ACBM) Shares Outstanding (Diluted Average) (2020 - 2025)

Acro Biomedical has reported Shares Outstanding (Diluted Average) over the past 6 years, most recently at $60.0 million for Q4 2025.

  • Quarterly results put Shares Outstanding (Diluted Average) at $60.0 million for Q4 2025, changed 0.0% from a year ago — trailing twelve months through Dec 2025 was $60.0 million (changed 0.0% YoY), and the annual figure for FY2025 was $60.0 million, changed 0.0%.
  • Shares Outstanding (Diluted Average) for Q4 2025 was $60.0 million at Acro Biomedical, roughly flat from $60.0 million in the prior quarter.
  • Over the last five years, Shares Outstanding (Diluted Average) for ACBM hit a ceiling of $60.0 million in Q3 2022 and a floor of $53.8 million in Q4 2021.
  • Median Shares Outstanding (Diluted Average) over the past 5 years was $60.0 million (2022), compared with a mean of $59.6 million.
  • Biggest five-year swings in Shares Outstanding (Diluted Average): grew 12.73% in 2021 and later changed 0.0% in 2023.
  • Acro Biomedical's Shares Outstanding (Diluted Average) stood at $53.8 million in 2021, then rose by 11.52% to $60.0 million in 2022, then changed by 0.0% to $60.0 million in 2023, then changed by 0.0% to $60.0 million in 2024, then changed by 0.0% to $60.0 million in 2025.
  • The last three reported values for Shares Outstanding (Diluted Average) were $60.0 million (Q4 2025), $60.0 million (Q3 2025), and $60.0 million (Q2 2025) per Business Quant data.